Evidence based radiation oncology: Breast cancer

Radiotherapy and Oncology

Volumn 84, Issue 1, 2007, Pages 84-101

  Poortmans, Philip ^a  

^a DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Breast conserving therapy; DCIS; Elective lymph node irradiation; Evidence based medicine; Locoregional radiotherapy; Postmastectomy radiotherapy; Radiotherapy; Review; Sequence

Indexed keywords

DOCETAXEL; TAMOXIFEN; TRASTUZUMAB;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL STUDY; ESTHETIC SURGERY; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; LUNG CARCINOMA; LYMPH NODE IRRADIATION; MASTECTOMY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; THORAX WALL; TREATMENT INDICATION; TREATMENT RESPONSE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIATION ONCOLOGY; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS;

EID: 34447264036     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.06.002     Document Type: Review

References (170)

1. Abner A.L., Recht A., Vicini F.A., et al. Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 21 (1991) 331-338
2. Ahn P.H., Vu H.T., Lannin D., et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23 (2005) 17-23
3. Albain K., Green S.J., Ravdin P.M., et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21 (2002) 37a
4. Antonini N., Jones H., Horiot J.C., et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC Trial 22881-10882. Radiother Oncol 82 (2007) 265-271
5. Aristizabal S.A., Miller R.C., Schlichtemeier A.L., Jones S.E., and Boone M.L.M. Adriamycin-irradiation cutaneous complications. Int J Radiat Oncol Biol Phys 2 (1977) 325-331
6. Azria D., Gourgou S., Sozzi W.J., et al. Concommitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 91 (2004) 1251-1260
7. Bartelink H., Garavaglia G., Johansson K.A., et al. Quality assurance in conservative treatment of early breast cancer. Report on a consensus meeting of the EORTC radiotherapy and breast cancer cooperative groups and the EUSOMA. Radiother Oncol 22 (1991) 323-326
8. Bartelink H., Horiot J.C., Poortmans P., et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345 (2001) 1378-1387
9. Beil D.R., and Wein L.M. Sequencing surgery, radiotherapy and chemotherapy: insights from a mathematical analysis. Breast Cancer Res Treat 74 (2002) 279-286
10. Belkacémi Y., and Vicini F. High-dose brachytherapy using MammoSite applicator: "Our doubts are traitors, And makes us lose the good we oft might win, By fearing to attempt!". Radiother Oncol 82 (2007) 354-355
11. Bellon J.R., Come S.E., Gelman R.S., et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 23 (2005) 1934-1940
12. Bellon J.R., and Harris J.R. Chemotherapy and radiation therapy for breast cancer: What is the optimal sequence?. J Clin Oncol 23 (2005) 5-7 [editorial]
13. Bellon J.R., and Harris J.R. What extent of radiation therapy is standard?. Breast 14 (2005) 532-540
14. Bentzen S., Skoczylas J., Overgaard M., et al. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 88 (1996) 918-922
15. Bijker N., Meijnen P., Peterse J.L., et al. Breast conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24 (2006) 3381-3387
16. Bijker N., Peterse J.L., Duchateau L., et al. Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19 (2001) 2263-2271
17. Blichert-Toft M., Rose C., Andersen J.A., et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr (1992) 19-25
18. Boice Jr. J.D., Harvey E.B., Blettner M., Stovall M., and Flannery J.T. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 326 (1992) 781-785
19. Borghero Y.O., Salehpour M., McNeese M.D., et al. Multileaf field-in-field forward-planned intensity-modulated dose compensation for whole-breast irradiation is associated with reduced contralateral breast dose: a phantom model comparison. Radiother Oncol 82 (2007) 324-328
20. Bouvet M., Ollila D.W., Hunt K.K., et al. Role of conservation therapy for invasive lobular carcinoma of the breast. Ann Surg Oncol 4 (1997) 650-654
21. Buijsen J., Jager J.J., Bovendeerd J., et al. Prone breast irradiation for pendulous breasts. Radiother Oncol 82 (2007) 337-340
22. Buzdar A.U., Smith T.L., and Powl K.C. Effect of timing of initiation of adjuvant chemotherapy and disease free survival in breast cancer. Breast Cancer Res Treat 2 (1998) 163-169
23. Chang H.Y., Nuyten D.S., Sneddon J.B., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102 (2005) 3738-3743
24. Chui C.S., Hong L., and McCormick B. Intensity-modulated radiotherapy technique for three-field breast treatment. Int J Radiat Oncol Biol Phys 62 (2005) 1217-1223
25. Chung M.A., Cole B., Wanebo H.J., Bland K.I., and Chang H.R. Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann Surg Oncol 4 (1997) 545-550
26. Coles C.E., Moody A.M., Wilson C.B., and Burnet N.G. Reduction of radiotherapy-induced late complications in early breast cancer: the role of intensity-modulated radiation therapy and partial breast irradiation. Part II - Radiotherapy strategies to reduce radiation-induced late effects. Clin Oncol (R Coll Radiol) 17 (2005) 98-110
27. Colleoni M., Bonetti M., Coate A.S., et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol 18 (2000) 584-590
28. Curran D., Van Dongen J.P., Aaronson N.K., et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast -conserving procedures: results of EORTC trial 10801. Eur J Cancer 34 (1998) 307-314
29. Cutuli B., Cohen-Solal-le Nir C., de Lafontan B., et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys 53 (2002) 868-879
30. Dalloz F., Maingon P., Cottin Y., Briot F., Horiot J.C., and Rochette L. Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. Free Radic Biol Med 26 (1999) 785-800
31. Dalton W.S., Brooks R.J., Jones S.E., et al. Breast cancer adjuvant therapy trials at the Arizona Cancer Center using adriamycin and cyclophosphamide. In: Samon E.S. (Ed). Adjuvant therapy of cancer V (1987), Grune and Stratton, Orlando 263-269
32. Darby S.C., McGale P., Taylor C.W., and Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol 6 (2005) 557-565
33. Denham J.W., Hamilton C.S., Christie D., et al. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer - toxicity and dose modification: a transtasman radiation oncology group multi-institution study. Int J Radiat Oncol Biol Phys 31 (1995) 305-313
34. Deutsch M., Land S.R., Begovic M., Wieand H.S., Wolmark N., and Fisher B. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 98 (2003) 1362-1368
35. Donovan E., Bleakley N., Denholm E., et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82 (2007) 254-264
36. Du X., Freeman J.L., Nattibger A.B., and Goodwin J.S. Survival of women after breast conserving surgery for early stage breast cancer. Breast Cancer Res Treat 72 (2002) 23-31
37. Dubey A., Recht A., Come S.E., et al. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 45 (1999) 877-884
38. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
39. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
40. Elkhuizen P.H., van de Vijver M.J., Hermans J., Zonderland H.M., van de Velde C.J., and Leer J.W. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 40 (1998) 859-867
41. Ernst M.F., Voogd A.C., Coebergh J.W.W., Poortmans P.M., and Roukema J.A. Using loco-regional recurrence as an indicator of the quality of breast cancer treatment. Eur J Cancer 40 (2004) 487-493
42. Ernster V.L., Barclay J., Kerlikowske K., Grady D., and Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275 (1996) 913-918
43. Ernster V.L., Barclay J., Kerlikowske K., Wilkie H., and Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160 (2000) 953-958
44. Farrus B., Vidal-Sicart S., Velasco M., et al. Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan. Int J Radiat Oncol Biol Phys 60 (2004) 715-721
45. Fiets W.E., Helvoirt van R.P., Nortier J.W.R., Tweel van der I., and Struikmans H. Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF versus AC) in breast cancer: a prospective comparative study. Eur J Cancer 39 (2003) 1081-1088
46. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
47. Fisher E.R., Dignam J., Tan-Chiu E., et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 86 (1999) 429-438
48. Fisher B., Dignam J., and Wolmark N. Tamoxifen in the treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 353 (1999) 1993-2000
49. Fisher B., Land S., Mamounas E., et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28 (2001) 400-418
50. Fogliata A., Nicolini G., Alber M., et al. IMRT for breast. A planning study. Radiother Oncol 76 (2005) 300-310
51. Freedman G.M., Fowble B.L., Nicolau N., et al. Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist?. Int J Radiat Oncol Biol Phys 46 (2000) 805-814
52. Fyles A.W., McCready D.R., Manchul L.A., et al. Tamoxifen with or without Breast Irradiation in Women 50 Years of Age or Older with Early Breast Cancer. N Engl J Med 351 (2004) 963-970
53. Gagliardi G., Lax I., Soderstrom S., Gyenes G., and Rutqvist L.E. Prediction of excess risk of long-term cardiac mortality after radiotherapy of stage I breast cancer. Radiother Oncol 46 (1998) 63-71
54. Giordano S.H., Kuo Y.F., Freeman J.L., Buchholz T.A., Hortobagyi G.N., and Goodwin J.S. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97 (2005) 419-424
55. Groome P.A., O'Sullivan B., Mackillop W.J., et al. Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys 64 (2006) 1002-1012
56. Guldner L., Haddy N., Pein F., et al. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer. Radiother Oncol 81 (2006) 47-56
57. Hamers H.P., Johansson K.A., Venselaar J.L.M., De Brouwer P., Hansson U., and D Moudi C. Entrance and exit TL-dosimetry in the conservative treatment of breast cancer: a pilot study for the EORTC Radiotherapy Cooperative Group. Radiother Oncol 22 (1991) 280-284
58. Harris E.E., Christensen V.J., Hwang W.T., Fox K., and Solin L.J. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 23 (2005) 11-16
59. Heimsoth I.M., Poortmans P., Collette L., et al. Radiation technique per patient compared to the radiation policy per institute and early toxicity in the EORTC trial 22922/10925 investigating the role of internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation in stage I to III breast cancer. Radiother Oncol 81 (2006) [abstract 93]
60. Heukelom S., Lanson J.H., Van Tienhoven G., and Mijnheer B.J. In vivo dosimetry during tangential breast treatment. Radiother Oncol 22 (1991) 169-279
61. Højris I., Overgaard M., Christensen J.J., and Overgaard J. Morbidity and mortality of ischemic heart disease in high-risk breast-cancer patients after adjuvant post-mastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet 354 (1999) 1425-1430
62. Holland P.A., Shah A., Howell A., et al. Lobular carcinoma of the breast can be managed by breast-conserving therapy. Br J Surg 82 (1995) 1364-1366
63. Hooning M.J., Aleman B.M., van Rosmalen A.J., Kuenen M.A., Klijn J.G., and van Leeuwen F.E. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys 64 (2006) 1081-1091
64. Hooning M.J., Botma A., Aleman B.M., et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99 (2007) 365-375
65. Houghton J., George W.D., Cuzick J., et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomized controlled trial. Lancet 362 (2003) 95-102
66. Huang J., Barbera L., Brouwers M., Browman G., and Mackillop W.J. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 21 (2003) 555-563
67. Hughes K.S., Schnaper L.A., Berry D., et al. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. N Engl J Med 351 (2004) 971-977
68. Hurkmans C.W., Borger J.H., Bos L.J., et al. Cardiac and lung complication probabilities after breast cancer irradiation. Radiother Oncol 55 (2000) 145-151
69. Hurkmans C.W., Borger J.H., Rutgers E.J., and van Tienhoven G. Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol 68 (2003) 233-240
70. Hurkmans C.W., Meijer G.J., van Vliet-Vroegindeweij C., van der Sangen M.J., and Cassee J. High-dose simultaneously integrated breast boost using intensity-modulated radiotherapy and inverse optimization. Int J Radiat Oncol Biol Phys 66 (2006) 923-930
71. Isaac N., Panzarella T., Lau A., et al. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer 95 (2002) 696-703
72. Janni W., Dimpfl T., Braun S., et al. Radiotherapy of the chest wall following mastectomy for early-stage breast cancer: impact on local recurrence and overall survival. Int J Radiat Oncol Biol Phys 48 (2000) 967-975
73. Johansen S., Olsen D.R., Danielsen T., and Malinen E. Contralateral breast doses following radiotherapy of the breast and regional lymph nodes: measurements and treatment planning calculations. Radiother Oncol 82 (2007) 332-336
74. Jones H.A., Antonini N., Hart G., et al. Significance of margins of excision on breast cancer recurrence. Eur J Cancer 147 (2004) [abstract 316]
75. Kaija H., and Mauna P. Tangential breast irradiation with or without internal mammary chain irradiation: results of a randomized trial. Radiother Oncol 36 (1995) 172-176
76. Korreman S.S., Pedersen A.N., Nøttrup T.J., Specht L., and Nyström H. Breathing adapted radiotherapy for breast cancer: comparison of free breathing gating with the breath-hold technique. Radiother Oncol 76 (2005) 311-318
77. Korreman S.S., Pedersen A.N., Josipović M., et al. Cardiac and pulmonary complication probabilities for breast cancer patients after routine end-inspiration gated radiotherapy. Radiother Oncol 80 (2006) 257-262
78. Kouloulias V.E., Poortmans P.M., Bernier J., et al. The quality assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC): a critical appraisal of 20 years of continuous efforts. Eur J Cancer 39 (2003) 430-437
79. Kurtz J.M., Jacquemier J., Torhorst J., et al. Conservation therapy for breast cancers other than infiltrating ductal carcinoma. Cancer 63 (1989) 1630-1635
80. Kurtz J.M., and Mirabell R. Radiation therapy and breast conservation: cosmetic results and complications. Semin Radiat Oncol 2 (1992) 125-131
81. Leer J.W., Caspers R.J., van Lonkhuijzen L.R., et al. Selective avoidance of postoperative locoregional radiotherapy in breast cancer seems to be justified. Eur J Surg 163 (1997) 815-822
82. Lievens Y., Poortmans P., and Van den Bogaert W. A glance on quality assurance in EORTC study 22922 evaluating techniques for internal mammary and medial supraclavicular lymph node chain irradiation in breast cancer. Radiother Oncol 60 (2001) 257-265
83. Lievens Y., and Van den Bogaert W. Internal mammary and medial supraclavicular lymph node irradiation: the thin line between advantages and side effects (editorial). Radiother Oncol 65 (2002) 75-77
84. Mai K.T., Yazdi H.M., and Isotalo P.A. Resection margin status in lumpectomy specimens of infiltrating lobular carcinoma. Breast Cancer Res Treat 60 (2000) 29-33
85. Major T., Niehoff P., Kovács G., Fodor J., and Polgár C. Dosimetric comparisons between high dose rate interstitial and MammoSite™ balloon brachytherapy for breast cancer. Radiother Oncol 79 (2006) 321-328
86. Marks L.B., Rosner G.L., Prosnitz L.R., Ross M., Vredenburgh J.J., and Peters W.P. The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer. Cancer 74 (1994) 2964-2971
87. Mayo C.S., Urie M.M., and Fitzgerald T.J. Hybrid IMRT plans - concurrently treating conventional and IMRT beams for improved breast irradiation and reduced planning time. Int J Radiat Oncol Biol Phys 61 (2005) 922-932
88. Mikeljevic J.S., Haward R., Johnston C., et al. Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. Br J Cancer 90 (2004) 1343-1348
89. Moore M.M., Borossa G., Imbrie J.Z., et al. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. Ann Surg 231 (2000) 877-882
90. Newman L.A., and Kuerer H.M. Advances in breast conservation therapy. J Clin Oncol 23 (2005) 1685-1697
91. Niehoff P., Polgár C., and Kovács G. In regard to Belkacémi and Vicini: high-dose brachytherapy using the MammoSite applicator "...Give me your hand, and let the subject see, to make them know". Radiother Oncol 82 (2007) 355-356
92. ® radiation therapy system for brachytherapy of breast cancer: Results from an international phase II trial. Radiother Oncol 79 (2006) 316-320
93. Oliver M., Chen J., Wong E., Van Dyk J., and Perera F. A treatment planning study comparing whole breast radiation therapy against conformal, IMRT and tomotherapy for accelerated partial breast irradiation. Radiother Oncol 82 (2007) 317-323
94. Omlin A., Amichetti M., Azria D., et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 7 (2006) 652-656
95. Ott O.J., Hildebrandt G., Pötter R., et al. Accelerated partial breast irradiation with multi-catheter brachytherapy: Local control, side effects and cosmetic outcome for 274 patients. Results of the German-Austrian multi-centre trial. Radiother Oncol 82 (2007) 281-286
96. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337 (1997) 949-955
97. Overgaard M., Jensen M.-J., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant Tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353 (1999) 1641-1648
98. Overgaard M., Nielsen H.M., and Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b & c randomized trials. Radiother Oncol 82 (2007) 247-253
99. Paszat L.F., Vallis K.A., Benk V.M.A., Groome P.A., Mackillop W.J., and Wielgosz A. A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. Radiother Oncol 82 (2007) 294-300
100. Peiro G., Bornstein B.A., Connolly J.L., et al. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 59 (2000) 49-54
101. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
102. Pierce L.J., Hutchins L.F., Green S.R., et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 23 (2005) 24-29
103. Pierce L.J., and Richer A.S. Postmastectomy radiotherapy: more than locoregional control. J Clin Oncol 12 (1994) 444-446
104. Poen J.C., Tran L., Juillard G., et al. Conservation therapy for invasive lobular carcinoma of the breast. Cancer 69 (1992) 2789-2795
105. Poortmans P. A bright future for radiotherapy in breast cancer. Radiother Oncol 82 (2007) 243-246 [editorial]
106. Poortmans P.M., Ataman F., Davis J.B., et al. Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period. Radiother Oncol 76 (2005) 278-284
107. Poortmans P., Bartelink H., Horiot J.C., et al. The influence of the boost technique on local control in breast conserving treatment in the EORTC "boost versus no boost" randomised trial. Radiother Oncol 72 (2004) 25-33
108. Poortmans P., Collette L., Horiot J.-C., et al. Impact of the boost dose on local control and survival in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10 years results of the randomised EORTC boost trial 22881/10882. Radiother Oncol 81 (2006) [abstract 54]
109. Poortmans P.M., Davis J.B., Ataman F., Bernier J., and Horiot J.C. The quality assurance programme of the Radiotherapy Group of the European Organisation for Research and Treatment of Cancer: past, present and future. Eur J Surg Oncol 31 (2005) 667-674
110. Poortmans P., Kouloulias V., van Tienhoven G., et al. Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works. Strahlenther Onkol 182 (2006) 576-582
111. Poortmans P., Kouloulias V.E., Venselaar J.L., et al. Quality assurance of EORTC trial 22922/10925 investigating the role of internal mammary - medial supraclavicular irradiation in stage I-III breast cancer: the individual case review. Eur J Cancer 39 (2003) 2035-2042
112. Poortmans P.M.P., Venselaar J.L.M., Struikmans H., et al. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC phase III randomized trial 22922/10925 in stage I-III breast cancer. Int J Radiat Oncol Biol Phys 49 (2001) 1399-1408
113. Ragaz J., Olivotto I.A., Spinelli J.J., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97 (2005) 116-126
114. Recht A. Integration of systemic therapy and radiation therapy for patients with early-stage breast cancer treated with conservative surgery. Comprehensive review. Clin Breast Cancer 4 (2003) 104-113
115. Recht A., Come S.E., Henderson I.C., et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 334 (1996) 1356-1361
116. Recht A., Gray R., Davidson N.E., et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17 (1999) 1689-1700
117. Remouchamps V.M., Huyskens D.P., Mertens I., et al. The use of magnetic sensors to monitor moderate deep inspiration breath hold during breast irradiation with dynamic MLC compensators. Radiother Oncol 82 (2007) 341-348
118. Romestaing P., Lehingue Y., Carrie C., et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 15 (1997) 963-968
119. Romestaing P., Ecochard R., Hennequin C., Bosset J.F., and Maingon P. The role of internal mammary chain irradiation on survival after mastectomy for breast cancer. Results of a phase III SFRO trial. Radiother Oncol 56 (2000) [abstract 306]
120. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
121. Rutgers E.J., Nortier J.W., Tuut M.K., et al. Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer". Ned Tijdschr Geneeskd 146 (2002) 2144-2151
122. Rutqvist L.E., Rose C., and Cavallin-Stahl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncol 42 (2003) 532-545
123. Salvadori B., Biganzoli E., Veronesi P., Saccozzi R., and Rilke F. Conservative surgery for infiltrating lobular breast carcinoma. Br J Surg 84 (1997) 106-109
124. Sanders M.E., Schuyler P.A., Dupont W.D., et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long term follow up. Cancer 103 (2005) 2481-2484
125. Sarrazin D., Le M.G., Arriagada R., et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 14 (1989) 177-184
126. Sartor C.I., Peterson B.L., Woolf S., et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol 23 (2005) 30-40
127. Sastre-Garau X., Jouve M., Asselain B., et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77 (1996) 113-120
128. Schmidberger H., Hermann R.M., Hess C.F., and Emons G. Interactions between radiation and endocrine therapy in breast cancer. Endocr Relat Cancer 10 (2003) 375-388
129. Schnitt S.J., Connolly J.L., Recht A., Silver B., and Harris J.R. Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer 64 (1989) 448-454
130. Senkus-Konefka E., and Jassem J. Complications of breast-cancer radiotherapy. Clin Oncol (R Coll Radiol) 18 (2006) 229-235
131. Shannon C., Ashley S., and Smith I.E. Does timing of adjuvant chemotherapy for early breast cancer influence survival?. J Clin Oncol 21 (2003) 3792-3797
132. Shapiro C.L., Harrigan-Hardenberg P., Gelman R., et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in node positive breast cancer patients. J Clin Oncol 16 (1998) 3493-3501
133. Silverstein M.J., and Buchanan C. Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. Breast 12 (2003) 457-471
134. Silverstein M.J., Lewinsky B.S., Waisman J.R., et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?. Cancer 73 (1994) 1673-1677
135. Singletary S.E., Patel-Parekh L., and Bland K.I. Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg 242 (2005) 281-289
136. Smith I.A., and Ross G.M. Breast radiotherapy after lumpectomy - no longer always necessary. N Engl J Med 351 (2004) 1021-1023
137. Stemmer S.M., Rizel S., Hardan I., et al. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study. J Clin Oncol 21 (2003) 2713-2718
138. Storm H.H., Andersson M., Boice Jr. J.D., et al. Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst 84 (1992) 1245-1250
139. Strom E.A., Woodward W.A., Katz A., et al. Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 1508-1513
140. Taghian A., Jeong J.H., Mamounas E., et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized trials. J Clin Oncol 22 (2004) 4247-4254
141. Taylor M.E., Perez C.A., Halverson K.J., et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 31 (1995) 753-764
142. Theodoulou M., and Seidman A.D. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol 30 (2003) 730-739
143. Thilmann C., Zabel A., Nill S., et al. Intensity-modulated radiotherapy of the female breast. Med Dosim 27 (2002) 79-90
144. In: Sobin L.H., and Wittekind Ch. (Eds). UICC TNM classification of malignant tumours. 6th ed. (2002), John Wiley & Sons, Hoboken (NJ)
145. van Asselen B., Schwarz M., van Vliet-Vroegindeweij C., Lebesque J.V., Mijnheer B.J., and Damen E.M.F. Intensity-modulated radiotherapy of breast cancer using direct aperture optimization. Radiother Oncol 79 (2006) 162-169
146. Van den Bogaert W, Struikmans H, Fourquet A, Bartelink H. Internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation in stage I-III breast cancer. A phase III randomised trial of the EORTC, protocol 22922/10925, May 1996, revision May 1999, Brussels.
147. Van den Broek N, Van der Sangen MJ, Van de Poll-Franse LV, van Beek MW, Nieuwenhuijzen GA, Voogd AC. Margin status and the risk of local recurrence after breast-conserving treatment of lobular breast cancer. Breast Cancer Res Treat, in press (PMID:17115109 [PubMed - as supplied by publisher]).
148. van der Leest M., Evers L., van der Sangen M.J.C., et al. The safety of breast-conserving therapy in breast cancer patients of 40 years and younger. Cancer 109 (2007) 1957-1964
149. Van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
150. van Dongen J.A., Voogd A.C., Fentiman I.S., et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 92 (2000) 1143-1150
151. van Nes J.G., and van de Velde C.J. The preferred treatment for young women with breast cancer - mastectomy versus breast conservation. Breast 15 (2006) S3-S10
152. Van Tienhoven G., Van Bree N.A.M., Mijnheer B.J., and Bartelink H. Quality assurance of the EORTC trial 22881/10882: "assessment of the role of the booster dose in breast conserving therapy": the Dummy Run. Radiother Oncol 22 (1991) 290-298
153. van't Veer L.J., Dai H., van de Vijver M.J., et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res 5 (2003) 57-58
154. van't Veer L.J., Dai H.Y., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
155. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (2002) 1227-1232
156. Veronesi U., Marubini E., Mariani L., Valagussa P., and Zucali R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer 35 (1999) 1320-1325
157. Vicini F.A., Kestin L.L., Goldstein N.S., et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol 18 (2000) 296-306
158. Voogd A.C., Nielsen M., Peterse J.L., et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19 (2001) 1688-1697
159. Voordeckers M., Van de Steene J., Vinh-Hung V., and Storme G. Adjuvant radiotherapy after mastectomy for pT1-pT2 node negative (pN0) breast cancer: Is it worth the effort?. Radiother Oncol 68 (2003) 227-231
160. Vrieling C., Collette L., Bartelink E., et al. Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. Int J Radiat Oncol Biol Phys 45 (1999) 667-676
161. Vrieling C., Collette L., Fourquet A., et al. The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. Int J Radiat Oncol Biol Phys 45 (1999) 677-685
162. Vrieling C., Collette L., Fourquet A., et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-concerving therapy in the EORTC "boost vs. no boost" trial. Radiother Oncol 55 (2000) 219-232
163. Vrieling C., Collette L., Fourquet A., et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. Eur J Cancer 39 (2003) 932-944
164. Wazer D., DiPetrillo T., Schmidt-Ullrich R., et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 10 (1992) 56-363
165. Wazer D., Tercilla O., Lin P., et al. Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17-estradiol and tamoxifen. Br J Radiol 62 (1989) 1079-1083
166. Whelan T.J., Julian J., Wright J., Jadad A.R., and Levine M.L. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18 (2000) 1220-1229
167. Whelan T., and Levine M. Radiation therapy and tamoxifen: concurrent or sequential? That is the question. J Clin Oncol 23 (2005) 1-4 [editorial]
168. White J.R., Gustafson G.S., Wimbish K., et al. Conservative surgery and radiation therapy for infiltrating lobular carcinoma of the breast. The role of preoperative mammograms in guiding treatment. Cancer 74 (1994) 640-647
169. Yarnold J., Ashton A., Bliss J., et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 75 (2005) 9-17
170. Yeatman T.J., Cantor A.B., Smith T.J., et al. Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 222 (1995) 549-559 [discussion 559-61]